RNAi typically leads to gene knockdown, reducing expression levels rather than eliminating them through silencing. This partial knockdown can be particularly advantageous when studying essential genes, as it allows researchers to explore gene function without causing lethality or developmental effects

RNA interference plays important roles in various cellular functions, including defense against viral infections and regulation of developmental processes. These small RNAs (for instance, small interfering RNAs, micro RNAs, and PIWI RNAs) activate ribonucleases, which then target and degrade complementary mRNA, effectively silencing gene expression and inhibiting protein translation.

Biochemical components involved in RNAi include small interfering RNA (siRNA), microRNA (miRNA), and the RNA-induced silencing complex (RISC). RISC consists of ribonuclease III (Dicer) and Argonaute proteins as subunits. These components work together to knockdown target genes by degrading or inhibiting the translation of specific mRNA molecules. This process enables gene regulation for research and therapeutic applications.

The discovery and mechanisms of RNA interference

RNAi was first discovered in the 1990s by researchers working with the petunia plant, who observed that introducing double-stranded RNA (dsRNA) led to gene silencing. In 2006, Andrew Z. Fire and Craig C. Mello received the Nobel Prize for physiology or medicine for their work on RNA interference (RNAi) in Caenorhabditis elegans. They showed that introducing dsRNA into the organism silenced genes with complementary sequences. These groundbreaking discoveries revealed a natural mechanism of gene regulation and opened up new avenues in gene therapy and biotechnology.

The foundational work of Fire and Mello was complemented by the discoveries in Arabidopsis thaliana, demonstrating RNAi as a universal biological process. One of the first discoveries was post-transcriptional gene silencing (PTGS), which causes selective mRNA degradation in Arabidopsis when transgenes or endogenous genes are overexpressed.

In Arabidopsis, short interfering RNAs (siRNAs), important RNAi mediators, were also discovered. These siRNAs provided a better understanding of RNA silencing mechanisms by directing the cleavage of target mRNA molecules.

Subsequent studies in Arabidopsis demonstrated the machinery involved in RNAi, including RNA-dependent RNA polymerases (RdRPs) that amplify the RNAi signal and Dicer-like (DCL) proteins that convert dsRNA into siRNAs.

Further research on Arabidopsis showed the ability of siRNAs to break down viral RNA through virus-induced gene silencing, demonstrating the role of RNAi in protecting plants from infections. Adding to the existing knowledge on the functions of RNAi in physiological and developmental processes was the discovery of trans-acting siRNAs, which control endogenous gene expression and were also discovered in studies on Arabidopsis.

RNAi is an essential tool in modern genetic research, enabling scientists to selectively knockdown genes and study their functions, including those related to the production of primary antibodies. It also holds promise for therapeutic applications, such as treating diseases caused by genetic mutations and viral infections, by potentially modulating the expression of specific genes involved in immune responses and antibody production.

Mechanism of RNA interference

RNAi is a natural cellular mechanism that regulates gene expression by controlling the stability and translation of mRNA. RNAi regulates gene expression through small RNA molecules like small interfering RNA (siRNA) and microRNA (miRNA), which guide RISC to target and silence complementary mRNA.

Small RNA molecules, such as siRNA and miRNA, involved in RNAi are derived from dsRNA cleaved by the enzyme Dicer. These fragments are incorporated into RISC, where one strand directs RISC to bind complementary mRNA sequences, leading to mRNA degradation or translational repression.

Role of siRNA and miRNA

siRNA and miRNA are key molecules used for RNAi that regulate gene expression by binding to target mRNA. siRNAs typically cause mRNA degradation, where miRNAs often inhibit translation or lead to mRNA cleavage. In animals, this process involves deadenylation and mRNA decay; in plants, it involves transcript cleavage.

siRNAs are 21–23 nucleotide dsRNA molecules that have been chemically produced or are transcribed. Computational approaches are used to design and produce siRNA with minimal off-target effects. Linkages like phosphorothioate or 2ʹ-O-methyl groups improve stability, minimize immunogenicity, and extend siRNA half-life. Additionally, selecting complementary sequences ensures silencing efficacy.

miRNAs are 21–25 nucleotide long, ubiquitously expressed RNAs in eukaryotic cells, and form stem-loop structures. They inhibit gene expression or induce transcription via mRNA-promoter binding. Canonically, miRNAs derive from pre-miRNAs processed by Dicer enzymes after nuclear export. Non-canonical pathways include “mirtrons” (spliced introns), Dicer-independent miRNAs processed by Drosha and cleaved by Ago2, or m7g-capped pre-miRNAs exported without Drosha cleavage.

Furthermore, clustered miRNAs are transcribed as long transcripts and cleaved, resulting in families that bind to similar seed areas. miRNAs are significant in disease research, particularly cancer research; however, their imprecise complementarity restricts precise gene silencing and in vitro testing. Despite their potential toxicity, miRNAs are primarily utilized to validate their impact on gene expression and cell phenotypes for therapeutic and research purposes.

RISC and its functions

• RISC is a multi-protein complex that plays a vital role in regulating gene expression. It leads to the degradation of mRNA molecules with the incorporation of small RNA molecules like miRNAs and siRNAs, which thereby guides the RISC to complementary RNA targets, resulting in the knockdown of the expression of the corresponding gene. The key components of RISC include:
• Argonaute (Ago) proteins are the core components of RISC. They serve as the catalytic engine of RISC by binding to the guide strand of the small RNA molecule. This binding enables the cleavage of target mRNAs when there is perfect complementarity. In cases of an imperfect match, they mediate translational repression. Among the Ago family members in mammals, only Ago2 retains endonuclease activity. It facilitates target RNA cleavage by pairing with highly complementary guide RNAs.
• Dicer is a ribonuclease that processes (“dices”) dsRNA precursors into siRNAs or miRNAs, typically 20–25 nucleotides long. Dicer proteins vary in number and function across species. In humans and Caenorhabditis elegans, a single Dicer facilitates the conversion of dsRNA into siRNAs and miRNAs. In contrast, organisms like Drosophila melanogaster have two Dicer paralogs: Dicer-1, which broadly participates in miRNA processing, and Dicer-2, which converts long dsRNA to siRNA. Plants, such as Arabidopsis, have many DCL proteins, DCL1-DCL4, each of which specializes in a different short RNA pathway. This variability reflects the evolution of RNAi systems to meet distinct regulatory needs across many organisms.
• The loading complex includes Dicer, Ago, and TRBP (transactivating response RNA-binding protein) or PACT (protein activator of PKR) in humans.
• Small RNAs (siRNAs and miRNAs) are sequence-specific guides that direct RISC to target mRNAs based on complementarity.
• Target mRNA is the substrate for RISC activity.

Differences between siRNA and miRNA pathways

The siRNA pathway typically begins with the introduction of exogenous dsRNA, which is cleaved by Dicer into siRNA. In contrast, miRNA is derived from endogenous primary transcripts, which are also processed by Dicer but from long, hairpin-shaped precursor RNA molecules.
Once processed, both siRNA and miRNA are incorporated into RISC, but siRNA generally targets and induces cleavage of perfectly complementary mRNA, while miRNA primarily inhibits translation or induces degradation of mRNA with partial complementarity. The biological roles of siRNAs often involve defense against viral infections and transposon silencing, whereas miRNAs are involved in the regulation of endogenous gene expression, developmental processes, and cellular differentiation.

Steps of RNA interference

The process of RNAi involves a series of precise steps that work together to regulate gene expression, starting with the introduction and formation of dsRNA into the cell and ending with the silencing of target genes. The dsRNA can be formed endogenously in cells:

• During the replication of positive-strand RNA viruses, dsRNA intermediates are formed as part of the viral life cycle.
• Transposable elements within the genome can produce dsRNA when both sense and antisense transcripts overlap and anneal. RNAi helps suppress transposon activity, maintaining genome stability.
• Natural transcription of non-coding RNAs or hairpin RNAs in some cells. Through complementary base pairing, these RNA molecules fold back on themselves and form dsRNA structures, contributing to post-transcriptional gene regulation, often being processed into siRNAs or miRNAs in RNAi pathways.
• Cellular responses to cells, like viral infections or DNA breaks, induce the formation of dsRNA through overlapping transcription or aberrant RNA processing.

dsRNAs can also be introduced in cells in the form of short hairpin RNA (shRNA). In contrast, small interfering RNA (siRNA) can be introduced in cells through electroporation, viral vectors, or lipid-based carriers to study gene function or develop therapeutic strategies.

Initiation

RNAi initiates with the presence of dsRNA in the cell. This dsRNA is recognized and cleaved by the Dicer enzyme, which chops it into smaller fragments known as siRNA.

RISC assembly and activation

The assembly and activation of RISC involves several key steps and subunits that facilitate gene regulation by knockdown. The small RNA is initially loaded into the RISC in a double-stranded form. Dicer and its cofactors such as TRBP facilitate this process.

The Dicer-loading complex includes Dicer, a class IV RNase III enzyme. Dicer contains domains, including helicase, RNase III, dsRNA-binding, and PAZ (containing Piwi/Ago/Zwille domains). This loading complex recognizes dsRNA or pre-micro RNAs through its PAZ domain and binds to the 3ʹ-overhangs of the substrate. It then cleaves the dsRNA with its RNase III domains, producing siRNAs or mature miRNAs with characteristic 2-nucleotide-long 3ʹ-overhangs.

Within the RISC, one strand of the siRNA, known as the guide strand, is retained, while the complementary passenger strand is cleaved and discarded by the action of the Ago protein, a core RISC component.

The activated RISC, containing a guide siRNA, binds to the target mRNA based on sequence complementarity between the siRNA and the mRNA, facilitating the targeting and degradation of the specific mRNA. Within the RISC, the Ago proteins (such as Ago2 in humans) mediate the recognition and cleavage of the target mRNA, thus functioning as the catalytic core.

The Ago protein also possesses PAZ and PIWI domains. Once a matching mRNA is recognized, the PIWI domain in the Ago protein facilitates endonucleolytic cleavage of the target mRNA, subsequently causing its degradation.

Other RISC subunits, such as TRBP, stabilize the interaction between siRNA generated through the Dicer and the RISC complex, ensuring efficient loading of the guide strand. Once bound, RISC initiates gene silencing by either of the two mechanisms:

mRNA degradation

When the pairing of the guide RNA within RISC is perfect or near perfect with its complementary sequence on the target mRNA, Ago2, the catalytic component of RISC, cleaves the mRNA into fragments. These fragments are then degraded by cellular exonucleases, thereby knocking down the expression of the gene encoded by that mRNA and preventing its translation into a protein.

This mechanism is precise as the sequence complementarity required between the guide RNA and the target mRNA is highly specific. The pathway of mRNA degradation can vary between organisms, reflecting evolutionary differences in RNAi machinery.

Translational repression

When the complementarity between the guide RNA (mostly microRNA or miRNA) and the target mRNA is partial, RISC does not cleave the mRNA but instead interferes with its translation. This interference potentially occurs through blockage of ribosome assembly, inhibition of elongation during translation, or premature ribosome dissociation.

Consequently, although this mRNA remains intact, it cannot be efficiently translated into protein because it is effectively knocked down. Additional mechanisms, such as mRNA deadenylation and decapping, may further reduce mRNA stability and translation efficiency.

RNAi amplification and DNA methylation in plants

RNAi in plants mediate both post-transcriptional gene silencing and persistent, heritable epigenetic changes. Amplification of the RNA signal is a key aspect of plant RNAi because it increases the silencing effect and maintains its persistence across numerous cellular generations. RdRPs are primarily responsible for this amplification, as they generate dsRNA from single-stranded RNA (ssRNA) templates. The knockdown effect is amplified, and the RNAi response spreads throughout the plant body, with the DCL proteins converting this secondary dsRNA into smaller interfering RNAs.

Aside from mRNA degradation, RNAi in plants mediates RNA-directed DNA methylation (RdDM), an essential step in transcriptional gene silencing. Herein, siRNAs derived from dsRNA under the action of RdRP direct Ago proteins to complementary DNA regions. This recruitment induces cytosine methylation by DNA methyltransferases de novo, effectively silencing the relevant gene at the transcriptional level. This methylation pattern can be maintained through both mitosis (cell division) and meiosis (gamete formation), resulting in long-term gene silencing.

Because of these phenomena, RNAi effects in plants can be persistently transmitted across succeeding generations, resulting in a heritable gene regulation mechanism. This heritability is significant in plant defense against transposable elements, viral infections, and environmental stress responses, ensuring adaptive genomic stability over generations.

RNA interference tools and technologies

RNAi research relies on various strategies and emerging technologies to achieve precise and efficient gene silencing.

Short hairpin RNA (shRNA)

ShRNA (short interfering RNA) is produced by cloning short gene fragments in the antisense orientation into plasmid-based or viral vectors, resulting in hairpin loop dsRNA. Dicer processes these shRNAs into siRNA-like molecules, which, in turn, promote RISC-induced targeting of the mRNAs for knockdown. shRNA systems use inducible or tissue-specific promoters to achieve persistent, regulated knockdown while minimizing cytotoxicity and off-target effects.

Synthetic siRNAs cause temporary effects; therefore, for long-term advantages, frequent introduction is required, although they enable quick and oftentimes effective gene knockdown with phenotypic changes observable within hours to a day.

Conversely, shRNAs provide longer-lasting knockdown as these systems can be constitutively expressed. Notwithstanding, using vectors to deliver shRNA presents issues of immunological reactions and possible insertional mutagenesis.

Nanoparticle delivery systems

Nanoparticles improve RNAi delivery by encapsulating siRNA or shRNA, shielding it from nucleases, and ensuring precise delivery. The specificity and efficiency are further enhanced in functionalized nanoparticles, including lipid nanoparticles (LNPs), polymeric nanoparticles (eg, PLGA), and inorganic nanoparticles (eg, gold and silica).

LNPs primarily comprise ionizable lipids, phospholipids, cholesterol, and lipids derived from polyethylene glycol that encapsulate and efficiently deliver the siRNA. LNPs are most commonly used in clinical settings due to their stability and absorption, whereas polymeric methods facilitate regulated release. Inorganic nanoparticles provide functional diversity. Nanoparticles are safer and less immunogenic than viral vectors, making them excellent for in vivo applications.

For example, intravitreal injection for treating hereditary transthyretin amyloidosis allows the transfer of genes to the eyes while avoiding retinal damage; however, this requires high viral titers, increasing the risk of side effects and immune activation. Thus, the first-ever LNP-based siRNA formulation was authorized by the FDA in 2018 for clinical treatment of this condition.

Other emerging technologies

Emerging technologies such as clustered, regularly interspaced short palindromic repeats (CRISPR) technologies allow for permanent gene editing. In contrast, RNAi is a powerful tool for transient gene silencing, allowing researchers to validate gene functions and evaluate therapeutic potential. RNAi employs small RNA molecules, like siRNAs or miRNAs, to degrade or inhibit the translation of target mRNA, leading to transient gene silencing.

CRISPR improves gene silencing through the use of a specially designed guide RNA to direct a modified, deactivated Cas9 enzyme (often called “dead Cas9”) to a specific location on the DNA, where it can physically block the transcription machinery, effectively preventing the targeted gene from being expressed without actually cutting the DNA, allowing for precise and highly efficient gene silencing at the transcriptional level.

When paired with nanoparticle delivery systems, CRISPR technologies improve the precision and efficiency of gene targeting and editing. For example, researchers applied CRISPR-Cas9 plasmids designed to reduce the production of toxic mutant Huntingtin (mHTT) protein to mesenchymal stem cells from YAC128 mice, a Huntingtin disease model, and observed a successful decrease in mHTT translation, highlighting CRISPR-Cas9’s potential for HD gene therapy.

Efficient and precise CRISPR/Cas9 delivery is crucial for maximizing therapeutic potential while minimizing off-target effects. Although viral delivery vectors are effective, they pose risks such as immunogenicity and mutation. Nanoparticles improve absorption, reduce transfer barriers, and boost genome editing efficiency.

Tools used in RNA interference research

siRNA design ensures efficient gene knockdown with optimal sequences, while shRNA expression systems and delivery methods like transfection and viral vectors enable targeted and stable gene knockdown in various cells.
The impact of RNAi is measured using a variety of assays, including cell-based, array, and enzymatic assays. To confirm siRNA-induced target knockdown, mRNA levels must be monitored closely. The ideal method for siRNA validation and transfection optimization is qRT-PCR, which compares target transcript levels in gene-specific and negative control siRNA-treated cells. Additionally, western blotting can be used to confirm the knockdown of the protein encoded by the targeted mRNA.

Synthetic siRNA design and synthesis

siRNA design is essential for efficient gene silencing, involving the selection of nucleotide sequences that are 21 bases long, starting with the AA dinucleotide, followed by 19 subsequent nucleotides from the target mRNA. Researchers recommend using siRNAs with 30–50% GC content and carefully choosing target sites to avoid off-target effects, often testing multiple sequences for optimal knockdown.

shRNA expression systems

shRNA expression systems are commonly used in RNAi research to knockdown target genes, with DNA-based vectors like plasmids and lentiviral vectors being popular tools. These systems allow efficient transfection or transduction into a variety of cell types, enabling prolonged gene knockdown and high-throughput screening for gene function analysis.

Delivery methods: transfection and viral vectors

Tools used in RNAi research include transfection reagents and viral vectors for delivering RNAi molecules into cells. Transfection reagents, such as lipid-based formulations, are often used for transient gene knockdown in a wide variety of cell types. At the same time, viral vectors are preferred for stable RNAi expression or use in difficult-to-transfect cells.

Fluorescent controls

Fluorescent controls are also used to monitor and assess the efficiency of RNAi delivery and transfection. These controls facilitate visualization of transfection effectiveness, allowing researchers to assess and modify experimental settings more efficiently. Fluorescent-labeled RNAi controls are detected through flow cytometry or fluorescence microscopy. The fluorescent signal is often localized to the nucleus, showing that cells take up RNAi efficiently. The fluorescent signal intensity correlates with ideal siRNA uptake settings, allowing for immediate and visible evaluation as well as exact modifications to maximize transfection efficiency.

Other controls used in RNAi studies include negative control siRNAs intended to prevent targeting any genes in experimental cells. They assist in distinguishing between sequence-specific knockdown effects and non-specific or off-target effects. The positive control siRNAs are used to check transfection efficiency in each experiment and serve as a standard for successful RNAi distribution.

Fluorescent controls in the assays involve the use of fluorescent-labeled molecules, such as siRNA constructs coupled with fluorescent dyes (eg, Cy3, Cy5, or Alexa fluor). Researchers can track the fluorescence signal to analyze in real-time the uptake and localization of RNAi molecules within cells.

Use of fluorescent controls

• RNAi molecule labeling: The RNAi molecule is tagged with a fluorescent dye (eg, siRNA). These dyes provide a detectable signal when excited by a particular wavelength of light, which can be detected using flow cytometry or visualized using a fluorescence microscope.
• Monitoring cellular uptake: During transfection, cells are exposed to fluorescently tagged RNAi molecules. The fluorescent signal reveals whether the RNAi molecule has entered the cells, allowing for assessment of the efficiency of delivery.
• Subcellular localization: Through the use of fluorescent controls, researchers can monitor the intracellular location of RNAi molecules and ensure the constructs are localized to the targeted cellular compartments where RNAi action occurs.
• Quantitative analysis: The efficiency of successfully transfected cells can be estimated by measuring the fluorescence intensity employing techniques such as flow cytometry. This information facilitates the optimization of transfection procedures.
• Verification of specificity: Appropriate interpretation of experimental outcome is facilitated; fluorescent controls also assist in differentiating between non-specific uptake by nearby cells and specific delivery to target cells.

Applications of RNA interference

RNAi enables gene knockdown to study gene functions, identify drug targets and disease pathways, explore potential therapies for genetic diseases, cancer, viral infections, and validate drug targets by observing phenotypic changes.

Applications in research

Functional genomics and gene knockdown studies

RNAi using siRNA is a powerful tool for functional genomics, enabling the selective knockdown of target genes to investigate their roles in biological processes, as it allows researchers to explore gene function without causing lethality or developmental effects. This technique helps identify key genes involved in disease pathways and provides insights into gene function in complex organisms.

Drug target identification

RNAi allows researchers to identify potential drug targets by selectively inhibiting genes and observing the resulting phenotypic changes. RNAi is, therefore, a helpful approach in the context of validating gene functions and discovering new therapeutic approaches for various diseases.

Applications in medicine

RNAi offers potential for gene therapy by silencing mutated genes in genetic diseases, inhibiting tumor growth in cancer, and targeting viral RNA for antiviral therapies and vaccine development.

Gene therapy for genetic diseases

RNAi holds promise for gene therapy, offering a method to silence mutated genes responsible for genetic diseases. This approach could provide treatments for conditions like Huntington’s disease, cystic fibrosis, and muscular dystrophy by targeting and silencing the defective genes. Patisiran, an siRNA that targets transthyretin, to treat adults with clinical atherosclerotic cardiovascular disease/heterozygous familial hypercholesterolemia and lowers LDL-C levels, was approved for clinical use in 2021. In another example, Givosiran, an RNAi therapeutic that targets ALA synthase-1, was approved for the treatment of a rare genetic condition called acute hepatic porphyriain 2019.

Potential in cancer treatment strategies

In cancer therapy, RNAi can be used to knockdown oncogenes or growth factors that drive tumor growth. Targeting these genes with siRNA has shown the potential to inhibit tumor progression and could complement other cancer treatments like chemotherapy and immunotherapy. Researchers have created photoresponsive antibody-siRNA conjugates (PARC) for photoactivable immunogene therapy and tumor-specific, photoinducible siRNA delivery. PARC is made up of a photocleavable linker that conjugates an α programmed death-ligand 1 (αPD-L1) antibody to siPD-L1. When PARC targets cancer cells, it internalizes and releases siPD-L1 when exposed to light. This suppresses cancer both in vitro and in vivo by inhibiting membrane PD-L1 activity and breaking down intracellular PD-L1 mRNA.

Use in antiviral therapies and vaccine development

RNAi is also being explored as a therapeutic strategy against viral infections, including HIV, hepatitis, and influenza, by targeting viral RNA and inhibiting replication. Additionally, RNAi may play a role in vaccine development by enhancing immune responses or targeting viral genes directly. For example, in targeting the mosquito-borne flavivirus Tembusu virus, adenovirus vectors have been used for RNA interference (RNAi)-based gene silencing. Engineered shRNAs generated from adenoviral vectors have demonstrated effective downregulation of TMUV RNA replication and viral production in Vero cells based on the sequences of the NS5 and TMUV E genes. The regulation of TMUV virus production persisted for at least 96 hours in a dose-dependent manner. Nonetheless, antiviral therapies employing RNAi are still in the research phase.

Advantages and limitations of RNA interference

RNAi offers high specificity for gene knockdown. However, challenges such as off-target effects and efficient delivery remain.

Benefits of RNA interference

RNAi offers high specificity in targeting and knocking down specific genes, making it an efficient tool for gene regulation and therapeutic applications. Its ability to selectively inhibit and modulate gene expression with minimal off-target effects makes it a promising approach for treating various diseases.

RNAi has broad potential across biological systems, enabling the study and manipulation of gene expression in a wide range of organisms. From plants, animals, and humans to unicellular organisms like yeast (Candida albicans), RNAi is a conserved process among eukaryotic organisms, highlighting its fundamental biological role across species. For instance, in both plants and animals, RNAi protects against viral infections, controls gene expression, maintains the stability of the genome, regulates immunological responses and developmental processes, and cell differentiation.

For example, in C. elegans, genes are silenced by Dicer, which converts dsRNA into siRNAs and directs the breakdown of target mRNA via RISC. Similarly, RNAi in A. thaliana protects against viruses by creating siRNAs that degrade viral genomes. Plants respond to environmental stress by modulating gene expression via PTGS-mediated RNAi. In the fungus Neurospora crassa, a similar RNAi-related process called quelling specifically silences genes associated with repetitive DNA sequences.

As RNAi is conserved across eukaryotes, it can be used in model organisms to provide insights that can be applied to a variety of biological systems. This versatility makes it an invaluable tool for both basic research and therapeutic applications in various fields, including oncology, virology, and genetic disorders.

Challenges and limitations

Off-target effects and toxicity are significant concerns in RNAi therapy, as unintended gene knockdown can lead to adverse reactions and disrupt cellular functions. These issues arise from the non-specific binding of RNA molecules, particularly with miRNAs, which can target multiple mRNAs, potentially affecting various biological pathways and causing toxicity.
Delivery challenges for therapeutic RNA applications include overcoming barriers such as RNA degradation in the bloodstream, inefficient cellular uptake due to their large size and negative charge, and difficulties in achieving targeted delivery to specific tissues or cells.

Ethical considerations for RNA-based therapies include risk-benefit analysis, patient consent, and equitable access, especially given the high costs and long-term uncertainties. Regulatory issues focus on ensuring safety, efficacy, and transparency in clinical trials while addressing potential risks like mutagenesis and unintended side effects.

For example, the results of a Phase II trial of a siRNA targeting PCSK9 found that it could efficiently reduce levels of LDL cholesterol. However, currently, there is no Phase III cardiovascular outcome trial data to prove that these RNA-based therapies ultimately improve cardiovascular outcomes. Studies demonstrating the effect of some of these therapies are currently underway (NCT04023552 and NCT03705234).

Overcoming current challenges

RNAi therapies have advanced with FDA-approved drugs and strategies like siRNA modifications, pooling, and sequencing to reduce off-target effects and improve stability and efficacy.

Strategies to reduce off-target effects

Chemically modifying siRNAs, especially at the seed region with 2ʹ-O-methylations or locked nucleic acids (LNAs), can help reduce miRNA-like off-target effects in RNAi by destabilizing interactions with partially complementary target sites.
Pooling multiple siRNAs targeting the same gene has also been shown to minimize off-target effects by reducing the likelihood that any single siRNA will bind to non-target sequences. Additionally, transcriptome sequencing can help identify and mitigate potential off-target interactions in large-scale RNAi screening experiments.

Emerging RNA interference technologies

CRISPR-Cas9 integration with RNAi enhances gene editing efficiency, while nanoparticle-based delivery systems improve RNAi therapy by protecting molecules and enabling targeted delivery.

CRISPR integration with RNAi

CRISPR-Cas9 integration with RNAi involves using artificial microRNAs (amiRNAs; designed RNA molecules to mimic natural microRNA structure and function) to target and control the expression of single guide RNA (sgRNA), thereby regulating the CRISPR system’s activity.

The CRISPR-Cas9 system uses sgRNA to guide Cas9 nuclease to specific DNA sequences, allowing targeted breaks in the double strand. As sgRNAs drive specificity and efficiency, unregulated activity can lead to off-target effects and unintended changes. CRISPR-Cas9 integration with RNAi-based regulation through amiRNAs overcomes these issues through optimization of sgRNA activity, enhancing precision, minimizing off-target effects, and increasing control over CRISPR-mediated editing.

amiRNAs, which imitate endogenous miRNAs, target sgRNAs by binding to their transcripts. This decreases sgRNA expression or alters its activity, providing fine temporal and spatial control over Cas9-mediated editing. This integration enhances the specificity, efficiency, and safety of gene-editing applications. The system reduces off-target effects through sgRNA regulation, enables dynamic control of CRISPR activity, and improves safety by minimizing the chance of accidental alterations. These features make it invaluable for clinical and research environments.

This approach is enhanced by small molecules like enoxacin, which promote the processing and loading of miRNAs onto the miRNA-induced silencing complex (miRISC), boosting the specificity of sgRNA targeting. The combined use of RNAi and CRISPR improves the efficiency of gene editing by blocking the influence of natural intracellular miRNAs on sgRNAs, therefore resolving challenges related to off-target effects and targeting precision.

Evolving RNA interference technologies

The siRNA-Finder (si-Fi) software optimizes RNAi construct design by predicting siRNA efficiency and identifying potential off-target effects, making it useful for specific gene knockdown applications. In experimental validation, si-Fi was used to design RNAi triggers targeting the HvMlo gene in barley, demonstrating its effectiveness in modulating gene expression and assessing RNAi specificity.

FAQs

How does RNA interference differ from CRISPR-Cas9?

RNA interference (RNAi) silences genes by targeting and degrading mRNA, effectively reducing gene expression at the transcriptional level. In contrast, CRISPR-Cas9 edits the genome directly by inducing double-strand breaks in DNA, leading to gene knockouts at the DNA level.

What role does the Dicer enzyme play in RNA interference?

Dicer is essential in antiviral RNA interference (RNAi) for processing double-stranded RNA (dsRNA) into small-interfering RNAs (siRNAs) that guide Argonaute proteins to suppress target viral genes post-transcriptionally. In addition to this role, Dicer (specifically DCL2) also participates in the siRNA-independent transcriptional induction of host genes through the

SAGA complex, which helps regulate viral replication and alleviate virus-induced symptoms.

Can RNA interference be used to treat all types of cancer?

RNA interference (RNAi) has been explored as a treatment for various cancers, including lung, pancreatic, breast, colorectal, ovarian, hepatocellular, gastric, and cervical cancers. It works by targeting specific genes involved in tumor growth, metastasis, and drug resistance, offering a promising approach to cancer therapy.